🐻 MEDP $18.3M Bearish Bet — Smart Money Loads Up on Deep ITM Puts Into Q1 Earnings Tonight

📅 April 22, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone dropped $18.3 MILLION on deep in-the-money MEDP puts at 9:43 this morning — two separate trades, same expiration, same minute, both buying protection with December 2026 strike prices of $570 and $560 while the stock was trading around $515. This isn't a cheap lottery ticket; these puts are already deep in the money, meaning the buyer is paying real intrinsic value plus a downside premium on a name that reports Q1 2026 earnings tonight after the close — the first print since a 15.9% single-session wipeout on February 10 and an active federal securities class-action lawsuit. With $18.3M on the line and a live litigation overhang, big money is clearly bracing for another leg down.

---

📊 Company Overview

Medpace Holdings (NASDAQ: MEDP) is a full-service clinical Contract Research Organization (CRO) headquartered in Cincinnati, Ohio:

• 🏥 What they do: Run Phase I–IV clinical trials for emerging biopharmaceutical companies — the mid-sized biotechs that need expert help getting drugs from the lab to FDA approval
• 💰 Market Cap: ~$14.73 billion (~28.6 million shares outstanding)
• 🏢 Industry: Services Allied to Motion Picture Production (SIC); Healthcare Services / CRO sector in practice
• 📊 52-Week Range: $250.05 low → $628.92 high (hit January 16, 2026)
• 📉 Current Spot: $514.83 on trade date — down roughly 18% from that January peak

Medpace's sweet spot is mid-cap emerging biotech sponsors — exactly the cohort that lives and dies by the biotech funding environment. When biotech funding tightens or sponsors cancel programs, Medpace feels it in cancellations and book-to-bill. That structural sensitivity is precisely what's been rocking this stock since February.

---

💰 The Option Flow Breakdown

📊 The Tape — April 22, 2026 @ 09:43:25

Total Premium: ~$18.3M | Same volume (923 contracts) | Same timestamp | Same expiration

🤓 What This Actually Means

Two things jump out immediately when you look at this tape:

First — these puts are deep in the money. With MEDP trading at $514.83, a $570 put has roughly $55 of intrinsic value alone. The buyer paid $101.84 for that contract. A $560 put has ~$45 of intrinsic value; they paid $96.42. You only buy deep ITM puts when you are genuinely bearish or need serious downside protection — this is not a speculative "lottery ticket" bet on a small move. This is structural hedging or outright conviction that MEDP is going lower.

Second — the timing is everything. Both trades hit at 9:43 a.m., barely 13 minutes after the open, on the morning of Q1 2026 earnings reporting tonight after the close. The buyer is not waiting to see what the print says. They are positioning ahead of the binary event, willing to pay a combined $18.3M to be protected (or positioned) before the market knows the results.

Real talk: whether this is a large MEDP long hedging their position or an outright bearish bet doesn't change the signal much. When someone pays this much for protection this far in the money on earnings day, they expect the stock can drop materially from here.

Why the $570 and $560 strikes? Those two strike levels sit above the post-February-10 gap zone — meaning a move back toward $446 (the February earnings lows) would put both positions deeply profitable. The buyer appears to be protecting against (or betting on) a retest of those post-shock lows if Q1 data disappoints.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

MEDP entered 2026 at an all-time high near $628.92 (reached January 16, 2026) before getting absolutely crushed on February 10's earnings shock, gapping from $530 down to $446 in a single session. Since that low the stock has ground back toward $515 — partially filling the gap — but remains 18% off the January peak. Tonight's Q1 print is a true binary: gap-fill resolution or a retest of the $446 low.

Key observations from the chart:

• 📉 The February gap is still open — $446 to $530 remains unresolved; tonight determines direction
• 🔄 Grinding recovery — the ~$515 handle represents a 3.5% monthly recovery from the February lows
• ⚠️ Failed to reclaim $530 — the February pre-announcement close is acting as technical resistance
• 📊 Volume elevated — options activity clustering around $514–$515 ahead of the earnings print signals binary positioning across the market

Gamma-Based Support & Resistance Analysis

Reading the GEX data from today's snapshot (current price ~$504.69 at time of GEX capture):

🔵 Support Levels (Put Gamma — Where Dealers Defend the Floor):

• $500 — Nearest and strongest support; total gamma 0.00517, net GEX positive. The round-number psychological level lines up with the highest nearby gamma exposure. This is your immediate line in the sand — a clean break here opens the door lower.
• $490 — Secondary support at total GEX 0.00300; modest floor but thin relative to $500
• $470 — Meaningful support with total GEX 0.00440; net GEX turns negative (put-gamma-dominated), meaning dealers buy aggressively here. This level roughly corresponds to a midpoint retracement toward the February lows.
• $450 — Major structural floor with total GEX 0.00675 (strongest below current price); net GEX deeply negative at -0.00096. This is the closest gamma anchor to the February post-earnings low of $446. If the stock revisits this zone, expect heavy dealer buying to cushion the move.
• $430 / $420 — Extended disaster-scenario floors; beyond these levels the put gamma concentration signals real stress.

🟠 Resistance Levels (Call Gamma — Where Dealers Cap Rallies):

• $510 — Immediate overhead resistance; despite being labelled a "resistance" level, the net GEX is slightly negative here meaning put pressure slightly dominates. This is a choppy zone.
• $520 — First clean resistance with total GEX 0.00551, net GEX -0.00127 (put-dominated). Dealers sell into strength here. The $520–$530 zone is the critical gap-fill ceiling.
• $560 — The SAME strike as one of today's put trades; total GEX 0.00822, call-dominated (net GEX +0.00767). Market makers hold big call gamma here — this level is a major ceiling on any rallies. The put buyer at $560 strike is essentially striking at the resistance wall.
• $600 — Extended resistance at total GEX 0.00462; represents the lower end of the gap to the January high.

Net GEX Bias: Bullish (total call GEX 0.053 vs put GEX 0.038) — but this is aggregate positioning. The near-term price action between $500 and $530 is where the real battle happens, and those levels are tightly contested.

Translation for regular folks: Think of $500 as a solid floor and $520–$530 as a ceiling on short-term rallies. A good earnings print likely pops the stock toward $530+ (gap-fill attempt). A bad print smashes through $500 and opens a road toward $450.

Implied Move Analysis

Options market pricing:

• 📅 Monthly OPEX (May 15, 2026 — 23 days away): Implied move of ±$63.58 (±12.57%) → Range: $442.11 – $569.26

Let that sink in. The options market is pricing a 12.57% swing through May 15 OPEX. With MEDP at $505 (at time of implied move capture), that lower bound of $442 lines up almost exactly with the February 10 post-earnings crash low of $446.05.

The upper bound of $569 sits just above the $560 put strike — meaning if MEDP squeezes toward $569, both of today's put positions (struck at $560 and $570) are at-the-money or underwater.

What does this tell us? The market is saying: either MEDP retests February's worst levels OR it stages a meaningful gap-fill recovery toward $570. There is almost no middle ground priced in — the implied move is calling for a decisive resolution of that open gap.

---

🎪 Catalysts

🔥 Right Now — Tonight Is The Moment of Truth

Q1 2026 Earnings — April 22, 2026 After Close

Medpace reports Q1 2026 results tonight with a follow-up call Thursday, April 23 at 9:00 a.m. ET. This is the first major earnings event since the February collapse and the market has been waiting.

What analysts expect per Yahoo Finance's earnings preview:

• 📊 Consensus Revenue: ~$694M (+24% YoY)
• 💰 Consensus EPS: ~$3.74 (+1.91% YoY)

But the revenue/EPS numbers are almost secondary. The one number that matters is the book-to-bill ratio. In Q4 2025, it came in at just 1.04 — far below the 1.10–1.25 range the firm historically delivered and well below management's flagged 1.15 run-rate. That single miss triggered the 15.9% plunge, the lawsuits, and months of skepticism.

A Q1 book-to-bill above 1.15 = bullish re-rating. Below 1.10 = another leg down. That's the trade.

⚠️ The Litigation Overhang — Active and Escalating

This is the factor that makes the MEDP trade story unique. Multiple securities class-action firms including Robbins LLP, Levi & Korsinsky, Wolf Haldenstein, and The Gross Law Firm have filed or are pursuing federal securities fraud complaints.

The complaint covers purchasers of MEDP stock from April 22, 2025 to February 9, 2026 and names CEO August Troendle, President Jesse Geiger, and CFO Kevin Brady — alleging they misled investors about the ~1.15 book-to-bill run-rate while cancellations, especially in metabolic programs, were quietly deteriorating. A bad Q1 print tonight would add evidentiary ammunition to these complaints and almost certainly spark another round of investor notices.

🧬 The GLP-1 Concentration Problem

Per the February 10 earnings call transcript, CEO August Troendle disclosed that cancellations were disproportionately concentrated in metabolic/GLP-1/obesity programs. This matters because:

• Eli Lilly's orforglipron (oral GLP-1) decision is expected in Q2 2026 — a major sector pivot point
• If the approval happens, it could accelerate competitor trial cancellations as second-tier GLP-1 programs get abandoned
• If it doesn't, the uncertainty continues depressing trial-start activity in metabolic medicine

Either way, Medpace's metabolic franchise exposure is a real concentration risk that the market is pricing into the options right now.

💚 The Bull Case — What Could Save the Bulls Tonight

To be fair, the macro backdrop for Medpace's business is actually strong:

• XBI ETF returned +40.80% over the trailing twelve months — the biotech funding environment Medpace depends on is healthy
• Biopharma IPOs raised $1.7B in Q1 2026 alone, the strongest IPO quarter since 2021 — more funded sponsors means more CRO contracts
• Q1 2026 biopharma venture funding reached $5.2B and M&A hit $15.6B — sponsor cohort is well-capitalized
• RBC Capital reiterated Buy heading into Q1 and Barclays upgraded from Underweight to Equal-Weight in March

Bulls argue the Q4 cancellation spike was a one-time flush of weak metabolic programs. If Q1 book-to-bill recovers, the February drop becomes an overreaction and there is real upside toward the $600+ January highs.

📅 Future Catalysts (Rest of 2026)

• Thursday, April 23, 2026 — Q1 earnings conference call at 9:00 a.m. ET; book-to-bill commentary and management tone will move the stock further
• Late July 2026 — Q2 2026 earnings; first full quarter under post-disclosure conditions
• Q2 2026 — FDA orforglipron (Eli Lilly oral GLP-1) decision; sector-defining for metabolic trial activity
• Late October 2026 — Q3 2026 earnings; first print with a full period of "normalized" cancellation data
• Ongoing — Class-action procedural milestones (lead plaintiff selection ~60 days post-filing, motion to dismiss briefing 6–9 months out)
• December 18, 2026 — Expiration of both today's put trades

---

🎲 Price Targets & Probabilities

Using today's gamma map, the implied move data, and the earnings setup:

📈 Bull Case (30% probability)

Target: $530 – $570 | Gap Fill Attempt

How we get there:

• 💪 Book-to-bill recovers above 1.15 — management narrative of "normalizing cancellations" is validated
• 📊 Revenue beats at $700M+ with stable margin commentary
• 🧬 Q1 metabolic cancellations confirm the GLP-1 shakeout is over, not ongoing
• 📈 Gap-fill move from $515 toward $530 (February pre-announcement close) and then onward toward $546–$569 implied move upper bound
• 🟠 The $560 gamma resistance level would be the first major ceiling in this scenario — note one of today's put buyers struck exactly at $560, so a rally to that level effectively makes that leg a breakeven wash
• 🎯 A clean gap-fill all the way to the $569–$570 zone would be the top of the near-term implied move range

Key milestone: The $530 level is the critical first test — it's both the technical gap-fill target AND the level MEDP was trading at just before the February blow-up. Breaking through there with conviction would likely attract fresh momentum buyers and short covering.

🎯 Base Case (30% probability)

Target: $480 – $530 | Choppy Limbo

Most likely near-term "no resolution" scenario:

• ✅ Revenue meets consensus, EPS acceptable
• 😐 Book-to-bill prints between 1.05 and 1.12 — slightly better than Q4's 1.04 but still not the clean recovery bulls need
• 🔄 Management reiterates full-year guidance with hedged language around metabolic; no meaningful update
• 📊 Stock oscillates in the $480–$530 zone; gamma support at $500 holds but the $520–$530 ceiling keeps upside capped
• 😰 Litigation commentary remains constrained; no financial reserve taken yet
• 💤 Implied volatility crush after the event compresses option premiums significantly

For the put holders: In this scenario, both puts retain meaningful intrinsic value ($30–$80 range) since the strikes are above the stock price, but significant upside (toward $446 retest) does not materialize. Positions are "in profit" but the big payout requires the bear case to play out.

📉 Bear Case (40% probability)

Target: $446 – $470 | February Lows Retest

What sends MEDP back to the lows:

• ❗ Book-to-bill prints at or below 1.04 again — confirms Q4 was not an anomaly but a trend
• 🧬 Management acknowledges continued metabolic program cancellations heading into Q2; GLP-1 shakeout is structural, not temporary
• 📉 Any downward guidance revision to the $2.755–$2.855B full-year revenue range
• ⚖️ Litigation commentary implies potential settlement reserves; adds overhang to EPS estimates
• 😰 Stock cracks $500 gamma support → cascade toward $470 (strong gamma floor), then $450 (strongest support level in GEX map)
• 🔨 Bears note: 10 of 18 analysts are already at Hold and consensus price target of $498 implies modest downside from current levels even before a bad print

The put positions in the bear case:

• $570 puts (paid $101.84): If MEDP trades at $446, intrinsic value = $124 → gain of ~$22.16/contract × 923 = ~$2.05M gain on the $9.4M investment
• $560 puts (paid $96.42): If MEDP trades at $446, intrinsic value = $114 → gain of ~$17.58/contract × 923 = ~$1.62M gain on the $8.9M investment
• Combined gain at $446: ~$3.67M on an $18.3M bet — a meaningful but not spectacular payout at the February retest level
• Bigger moves (toward $420–$430 gamma floors) would significantly increase the payout

Why 40% probability? The binary setup, the active litigation, the fact that book-to-bill has already disappointed once, and the concentration in metabolic programs that has an uncertain near-term trajectory all skew the risk-reward toward the downside. The put buyer clearly agrees — you don't spend $18.3M on deep ITM puts two hours before market open on earnings day unless you have a strong view.

---

💡 Trading Ideas

🛡️ Conservative: Wait for the Print, Then Decide

Play: Do not enter any position until after tonight's earnings and tomorrow's conference call

Why this works:

• ⏰ With earnings tonight, options are extremely expensive right now due to elevated implied volatility — paying up for premium today means IV crush tomorrow will work against any position you put on
• 📊 The 12.57% implied move means a $63 swing is priced in — that is a massive two-sided risk for any short-dated position
• 🎯 After the print, the story becomes clearer: either gap-fill bull mode or retest-the-lows bear mode — both have better entry opportunities post-event
• 👀 Watch for book-to-bill first; everything else follows from that single number

Action plan:

• Tonight: Do not trade ahead of the event
• Tomorrow pre-market: Read the actual Q1 release, focus on book-to-bill, metabolic commentary, and any guidance changes
• Post-call Thursday: Decide direction based on clean information, not guesswork
• If bearish: Look for puts on $500–$510 strikes at much lower premium cost after IV crush
• If bullish: Look for calls targeting the $530–$546 gap-fill zone after IV deflates

Risk level: Minimal | Skill level: Beginner-friendly

Expected outcome: Avoid the binary event risk entirely; get a better risk-adjusted entry with factual data in hand.

⚖️ Balanced: Post-Earnings Bear Put Spread (If Book-to-Bill Disappoints)

Play: If Q1 book-to-bill prints below 1.10 and stock gaps toward $480–$490, buy a put spread for the continued move lower

Structure example: Buy $490 put / Sell $450 put (December 2026 expiration — same cycle as today's big trade)

Why this works:

• 🎢 After the binary event resolves bearishly, IV will crush from elevated pre-earnings levels — put spreads become much cheaper than buying outright puts
• 🎯 The $450 gamma support level (GEX: strongest support in the entire map at total 0.00675) acts as a natural target and anchor — you sell puts there to reduce cost
• 📊 Defined risk ($40 wide spread = $4,000 max risk per spread); your maximum loss is known going in
• ⏰ December 2026 expiration gives 8 months for the litigation overhang and book-to-bill deterioration thesis to play out
• 🤝 You are essentially following the same playbook as today's $18.3M buyer but at a fraction of the cost, after confirmation

Estimated P&L (rough post-event estimates):

• 💰 Net debit: ~$12–$18 per spread after IV crush (down from pre-earnings prices)
• 📈 Max profit: ~$22–$28 if MEDP closes below $450 at December expiration
• 📉 Max loss: ~$12–$18 if MEDP stays above $490
• 🎯 Breakeven: ~$472–$478

Entry timing:

• ⏰ Only enter Thursday morning or after, once the print is confirmed negative
• ❌ Do not enter this spread if book-to-bill beats 1.15 — the thesis is invalidated

Position sizing: Keep to 3–5% of portfolio max; this is a directional thesis play, not a hedge.

Risk level: Moderate (defined risk, bearish directional) | Skill level: Intermediate

🚀 Aggressive: Ride Along With the Whale — Deep ITM Puts (Advanced Only)

Play: If you share the bearish conviction of today's buyer, consider a smaller scale version of the same trade — December 2026 deep ITM puts on a post-earnings gap higher (if stock rallies toward $530 after any initial positive reaction)

Structure: 1–3 contracts of the December 2026 $540–$550 puts if MEDP briefly pops toward $530+ post-earnings before rolling over

Why this could work:

• 🐋 You are following institutional money that spent $18.3M on the same expiration — the largest smart-money signal in this name in recent memory
• 🧬 If Q1 delivers a "not as bad as feared" relief rally, that pop to $530+ gives you a better entry on bearish positioning for the ongoing litigation and Q2 book-to-bill uncertainty
• 📊 December 2026 expiration gives you three more earnings prints for the thesis to develop — Q2, Q3 guidance, and litigation developments all within the window
• 🎯 The $446 February low and the $442 implied move floor are your near-term targets; a move there from $530 would be a ~16% decline fully captured in deep ITM puts

Serious risks to acknowledge:

• 💸 Deep ITM options are expensive — a $540 put with MEDP at $530 costs roughly $55–$65 per contract ($5,500–$6,500 each); 3 contracts = $16,500–$19,500 at risk
• ✅ If book-to-bill smashes expectations and MEDP gaps to $560+, your puts lose intrinsic value dollar-for-dollar — you need a hard stop
• ⚠️ You are fighting the macro tail-wind (strong XBI, biotech IPO recovery) if it translates into demand recovery for Medpace faster than expected
• 📊 The litigation could settle for less than feared, removing a major overhang and allowing re-rating

Hard rules if you take this trade:

• ✅ Only enter on a pop to $530+ (not at current levels)
• ✅ Limit to 1–3 contracts maximum (this is a high-conviction speculative trade, not a portfolio cornerstone)
• ✅ Set a mental stop if MEDP closes above $565 on sustained volume
• ✅ Plan to hold through Q2 2026 earnings for full thesis development
• ✅ Read the actual Q1 transcript yourself before entering

Risk level: High (can lose significant premium on a wrong directional call) | Skill level: Advanced only

---

⚠️ Risk Factors

Do not ignore these before trading MEDP:

• 📊 Book-to-bill beat risk: If Q1 book-to-bill prints at 1.15+ and metabolic commentary is constructive, the entire bear thesis deflates. Both of today's put positions — despite being deep ITM — would see intrinsic value decline point-for-point if the stock rallies toward the $560 strikes. There is no "safe" bearish play here if the fundamental data reverses.

• ⚖️ Litigation is not a guaranteed negative: Multiple class-action complaints are allegations, not proven facts. If the motion to dismiss succeeds or an early settlement comes in well below feared amounts, the litigation overhang lifts and could trigger a sharp re-rating higher.

• 🌐 Biotech funding environment is genuinely strong: The XBI is up 40.8% over twelve months, Q1 2026 biopharma IPOs raised $1.7B, and venture funding totaled $5.2B in Q1. This is the best funding backdrop for Medpace's client base since 2021. If that translates into fresh RFP activity, the book-to-bill problem may resolve faster than bears expect.

• 🧬 GLP-1 sector resolution could be a positive: The pending Eli Lilly orforglipron approval decision expected Q2 2026 is a two-sided event. If orforglipron gets approved, it could reignite metabolic trial activity across the ecosystem — including Medpace's pipeline — rather than further depressing it.

• 💸 Deep ITM options carry full intrinsic value risk: These are not cheap options. The buyer paid $101.84 and $96.42 per contract — both include significant intrinsic value. If MEDP rallies 10–12% tonight on a strong print, both positions lose real money fast. Unlike OTM options where you lose only time premium, with deep ITM puts you are losing intrinsic value dollar for dollar on a rally.

• 📉 Valuation is not extreme: At ~$515 and roughly 29x the midpoint of 2026 EPS guidance, MEDP is at a historically fair multiple for the business. It is not wildly expensive — which means a good print could re-rate it quickly without the "priced for perfection" ceiling that caps some recovery moves.

• 🎢 Implied volatility crush is brutal: If you buy options today (any direction), you are paying inflated implied volatility. The moment the earnings number drops, IV will compress sharply. Even if you are directionally right, a smaller-than-implied move will cost you money on premium decay.

---

🎯 The Bottom Line

Here's the deal: Two institutional-scale put trades, $18.3M combined, hitting at the exact same minute on the morning of Q1 earnings — with both strikes ($570 and $560) sitting well above the current stock price (~$515) and both expiring December 18, 2026. These are not cheap bets. These are heavy, conviction-driven positions in a name that already blew up once on a book-to-bill miss and is carrying active federal securities fraud litigation against its top three executives.

What this trade tells us:

• 🐻 Whoever bought these puts does not expect a clean Q1 recovery — if they did, they would not have paid $18.3M for protection going into a binary event
• 📊 The December 2026 expiration captures Q2, Q3, and potentially Q4 earnings, plus all of the litigation procedural milestones — this is a long-duration bearish thesis, not a quick trade
• 🎯 The $560 strike is significant — it sits exactly at the strongest gamma resistance level in the GEX map, where market maker call gamma peaks. The buyer is not just betting MEDP goes down; they are betting it stays well below that ceiling.
• 💰 At $18.3M total premium, these contracts protect or profit on roughly 1.84 million notional shares of MEDP — a position size that reflects genuine institutional scale

If you currently own MEDP stock:

• ✅ Tonight's print is genuinely binary — have a plan before it happens
• 📊 If book-to-bill disappoints again, seriously consider trimming or buying protection; the litigation narrative gets louder with each miss
• 🎯 If the stock pops on a beat, the $530 and $546 technical resistance levels are where sellers will show up — do not assume gap-fill means new highs immediately

If you are watching from the sidelines:

• ⏰ Tonight after close and Thursday morning are the moments of truth — wait for the actual data
• 🎯 Post-earnings, if the stock drops toward $470–$450, the gamma analysis shows significant dealer buying around $450 — that is your best risk-adjusted entry on either direction with clean information in hand
• 📅 Mark your calendar: Thursday April 23 at 9:00 a.m. ET is the earnings call — the Q&A session on book-to-bill will be where the real signal comes from
• ⚠️ Do not chase the first 10 minutes of post-earnings price action; let the initial move settle and the call transcript absorb

If you share the bearish view:

• 🐻 The institutional buyer has done the heavy lifting — do not blindly copy a position without understanding the risks of $100+ option prices losing value on a rally
• 📊 Consider waiting for a post-print entry if bearish (defined risk put spread on a bounce, not buying in front of the binary)
• 🎯 Key downside levels to watch: $500 gamma floor (first break signal), $470 (intermediate support), $450 (strongest gamma support and implied move lower bound) — the $446 February low is the ultimate test

Final verdict: Medpace is at a genuine crossroads tonight. The business operates in a strong macro environment, but one badly managed book-to-bill metric has triggered 18% losses from the January high, active litigation, and now $18.3M of institutional put buying less than an hour into the trading day on earnings morning. The risk/reward heading into the print is skewed to the downside — the put buyer's positioning confirms it, the litigation confirms it, the GLP-1 concentration risk confirms it. But a clean Q1 print with book-to-bill recovery toward 1.15+ would make tonight a legitimate buying opportunity into a well-run CRO at a fair valuation with a recovering funding backdrop.

Be patient. Let the print speak. Protect your capital. The story clarifies tonight.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational and informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Past unusual options activity does not guarantee future returns. Deep in-the-money options carry significant dollar risk and can lose substantial value on adverse price moves. The $18.3M institutional put trades described may reflect hedging of existing positions rather than directional speculation, and may not be suitable for retail traders with different portfolio sizes and risk profiles. Earnings events create binary risk with potential for large gaps in either direction — always manage position sizes accordingly and consult a licensed financial advisor before making investment decisions.

---

About Medpace Holdings: Medpace Holdings, Inc. is a full-service clinical Contract Research Organization (CRO) providing Phase I–IV clinical trial support for emerging biopharmaceutical sponsors, with a market capitalization of approximately $14.73 billion. The company is headquartered in Cincinnati, Ohio and employs between 5,000 and 10,000 professionals globally across North America, Europe, and Asia.